Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/LPP_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/LPP_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/LPP_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/LPP_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/LPP_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/LPP_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/LPP_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/LPP_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/LPP_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/LPP_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/LPP_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/LPP_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/LPP_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009030317 | Thyroid | HT | positive regulation of wound healing | 14/1272 | 59/18723 | 3.06e-05 | 6.55e-04 | 14 |
GO:001063425 | Thyroid | HT | positive regulation of epithelial cell migration | 26/1272 | 176/18723 | 1.47e-04 | 2.26e-03 | 26 |
GO:006104120 | Thyroid | HT | regulation of wound healing | 21/1272 | 134/18723 | 2.73e-04 | 3.75e-03 | 21 |
GO:001063224 | Thyroid | HT | regulation of epithelial cell migration | 36/1272 | 292/18723 | 3.84e-04 | 4.84e-03 | 36 |
GO:000166728 | Thyroid | HT | ameboidal-type cell migration | 52/1272 | 475/18723 | 4.54e-04 | 5.53e-03 | 52 |
GO:001063126 | Thyroid | HT | epithelial cell migration | 41/1272 | 357/18723 | 6.87e-04 | 7.77e-03 | 41 |
GO:009013226 | Thyroid | HT | epithelium migration | 41/1272 | 360/18723 | 8.11e-04 | 8.78e-03 | 41 |
GO:001605520 | Thyroid | HT | Wnt signaling pathway | 48/1272 | 444/18723 | 9.68e-04 | 9.93e-03 | 48 |
GO:009013026 | Thyroid | HT | tissue migration | 41/1272 | 365/18723 | 1.06e-03 | 1.07e-02 | 41 |
GO:019873820 | Thyroid | HT | cell-cell signaling by wnt | 48/1272 | 446/18723 | 1.07e-03 | 1.07e-02 | 48 |
GO:005109010 | Thyroid | HT | regulation of DNA-binding transcription factor activity | 46/1272 | 440/18723 | 2.39e-03 | 2.03e-02 | 46 |
GO:006007019 | Thyroid | HT | canonical Wnt signaling pathway | 34/1272 | 303/18723 | 2.76e-03 | 2.27e-02 | 34 |
GO:005109110 | Thyroid | HT | positive regulation of DNA-binding transcription factor activity | 30/1272 | 260/18723 | 3.15e-03 | 2.52e-02 | 30 |
GO:004354218 | Thyroid | HT | endothelial cell migration | 31/1272 | 279/18723 | 4.78e-03 | 3.29e-02 | 31 |
GO:003011120 | Thyroid | HT | regulation of Wnt signaling pathway | 35/1272 | 328/18723 | 5.41e-03 | 3.58e-02 | 35 |
GO:00105949 | Thyroid | HT | regulation of endothelial cell migration | 26/1272 | 232/18723 | 8.27e-03 | 4.78e-02 | 26 |
GO:00105959 | Thyroid | HT | positive regulation of endothelial cell migration | 17/1272 | 133/18723 | 8.71e-03 | 4.93e-02 | 17 |
GO:004819320 | Thyroid | PTC | Golgi vesicle transport | 186/5968 | 296/18723 | 3.09e-28 | 1.22e-25 | 186 |
GO:0031647113 | Thyroid | PTC | regulation of protein stability | 174/5968 | 298/18723 | 2.05e-21 | 4.05e-19 | 174 |
GO:0050821113 | Thyroid | PTC | protein stabilization | 115/5968 | 191/18723 | 5.67e-16 | 4.31e-14 | 115 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LPP | SNV | Missense_Mutation | rs749505857 | c.1396G>A | p.Glu466Lys | p.E466K | | protein_coding | deleterious(0) | possibly_damaging(0.889) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
LPP | SNV | Missense_Mutation | | c.922N>C | p.Gly308Arg | p.G308R | | protein_coding | tolerated(0.11) | possibly_damaging(0.818) | TCGA-A1-A0SH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tc | SD |
LPP | SNV | Missense_Mutation | rs756003756 | c.1457G>A | p.Arg486Gln | p.R486Q | | protein_coding | deleterious(0) | possibly_damaging(0.74) | TCGA-A1-A0SM-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LPP | SNV | Missense_Mutation | | c.254N>G | p.Ser85Cys | p.S85C | | protein_coding | tolerated(0.05) | benign(0.276) | TCGA-A7-A26G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
LPP | SNV | Missense_Mutation | | c.1834N>G | p.Leu612Val | p.L612V | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.974) | TCGA-A8-A083-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LPP | SNV | Missense_Mutation | novel | c.1576N>A | p.Glu526Lys | p.E526K | | protein_coding | deleterious(0) | possibly_damaging(0.57) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LPP | SNV | Missense_Mutation | novel | c.1274N>T | p.Gly425Val | p.G425V | | protein_coding | deleterious(0) | possibly_damaging(0.874) | TCGA-AC-A2QH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
LPP | SNV | Missense_Mutation | | c.1391N>G | p.Tyr464Cys | p.Y464C | | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
LPP | SNV | Missense_Mutation | novel | c.452N>G | p.Ser151Cys | p.S151C | | protein_coding | deleterious(0.02) | possibly_damaging(0.885) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
LPP | SNV | Missense_Mutation | | c.1751N>A | p.Cys584Tyr | p.C584Y | | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |